Clinical trials: Ranibizumab, active
Diabetic Macular Edema (DME)
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
A multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment.
- Trial name
- NCT07515079
- Testing
- BAT5906 injection, Lucentis
- Where
- 50 sites in China
- Volunteers
- 406 people
- Sponsor
- Bio-Thera Solutions
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration
Changes in Intraocular Pressure After Intravitreal Injection
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP).
- Conditions
- Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Retinal Vein Occlusion, Ocular Hypertension
- Trial name
- NCT07826286
- Volunteers
- 50 people
- Sponsor
- Assiut University
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration (nAMD)
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered…
- Trial name
- NCT04657289
- Testing
- Ranibizumab, Port Delivery System with Ranibizumab
- Where
- 104 sites in Argentina, Australia and 14 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Age-related Macular Degeneration
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab [1] and aflibercept [2]…
- Trial name
- FAR-WEST (NCT06271330)
- Testing
- Faricimab
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema (DME)
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BAROLO (NCT06957080)
- Testing
- Remigromig, Ranibizumab
- Where
- 164 sites in United States, Argentina and 4 more
- Volunteers
- 1,054 people
- Sponsor
- EyeBiotech Ltd.
Neovascular Age-related Macular Degeneration
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients.
- Trial name
- nAMD (NCT05461339)
- Testing
- TAB014 Monoclonal Antibody Injection, Ranibizumab Injection [Lucentis]
- Where
- 56 sites in China
- Volunteers
- 488 people
- Sponsor
- BioDlink Biopharm Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Trial name
- 4 PORT (NCT07864480)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Southeast Retina Center, Georgia
Neovascular Age-related Macular Degeneration, nAMD
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks…
- Trial name
- HUTONG (NCT05562947)
- Testing
- PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL)
- Where
- 14 sites in China
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration
LEAP Strategy for Neovascular Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and…
- Trial name
- LEAP (NCT07744204)
- Testing
- Laser photocoagulation, Anti-VEGF agents
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 64 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema, Diabetic Retinopathy
Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema
This is a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of levosulpiride to improve retinal alterations due to diabetic macular edema and diabetic retinopathy
- Trial name
- NCT03161652
- Testing
- DME lactose pill, DME levosulpiride, DR lactose pill
- Where
- 2 sites in Mexico
- Volunteers
- 120 people
- Sponsor
- Carmen Clapp
Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet)…
- Trial name
- AAVIATE (NCT04514653)
- Testing
- Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 146 people
- Sponsor
- AbbVie
Wet Age-related Macular Degeneration
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation…
- Trial name
- AMD (NCT06952452)
- Testing
- Bevacizumab, Ranibizumab Ophthalmic
- Where
- 4 sites in Spain
- Volunteers
- 630 people
- Sponsor
- Parc de Salut Mar
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
- Trial name
- Belvedere (NCT04853251)
- Testing
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Where
- 40 sites in United States
- Volunteers
- 188 people
- Sponsor
- Genentech, Inc.